The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The high frequency of RAS mutations in human cancers (33%) has stimulated intense interest in the development of anti-Ras inhibitors for cancer therapy. Currently, the major focus of these efforts is centered on inhibitors of components involved in Ras downstream effector signaling. In particular, more than 40 inhibitors of the Raf-MEK-ERK mitogen-activated protein kinase cascade and phosphoinositide 3-kinase-AKT-mTOR effector signaling networks are currently under clinical evaluation. However, these efforts are complicated by the fact that Ras can utilize at least 9 additional functionally distinct effectors, with at least 3 additional effectors with validated roles in Ras-mediated oncogenesis. Of these, the guanine nucleotide exchange factors of the Ras-like (Ral) small GTPases (RalGEFs) have emerged as important effectors of mutant Ras in pancreatic, colon, and other cancers. In this review, we summarize the evidence for the importance of this effector pathway in cancer and discuss possible directions for therapeutic inhibition of aberrant Ral activation and signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706
Self-citationTargeting the PI3K signaling pathway in cancer
Wong, K.-K., Engelman, J. A., & Cantley, L. C. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.002 · Cited by 543
The exocyst is a Ral effector complex
Moskalenko, S., Henry, D. O., Rosse, C., Mirey, G., Camonis, J. H., & White, M. A. (2002) · Nature Cell Biology · doi:10.1038/ncb728 · Cited by 423 · cited 2×
“Perhaps the best characterized of the Ral effectors are 2 components of the octameric exocyst complex (also called Sec6/8 complex), Sec5 and Exo84.(56,57) The octameric exocyst complex is involved in the regulation of exocytosis.”
BackgroundActivation of RalA is critical for Ras-induced tumorigenesis of human cells
Lim, K.-H., Baines, A. T., Fiordalisi, J. J., Shipitsin, M., Feig, L. A., Cox, A. D., Der, C. J., & Counter, C. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.030 · Cited by 355 · cited 1×
“That these 2 highly related proteins could serve opposing functions in transformed growth has been described previously in studies with Ras-transformed, immortalized human embryonic kidney epithelial cells.(98) Interestingly, these results contrast with observations made with transient RalB suppression in CRC cells th…”
ResultSelf-citationBridging Ral GTPase to Rho Pathways
Jullien-Flores, V., Dorseuil, O., Romero, F., Letourneur, F., Saragosti, S., Berger, R., Tavitian, A., Gacon, G., & Camonis, J. H. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.38.22473 · Cited by 338
Rodriguez-Viciana, P., Sabatier, C., & McCormick, F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.11.4943-4954.2004 · Cited by 327
Cantor, S. B., Urano, T., & Feig, L. A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4578 · Cited by 310
Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator.
Hofer, F., Fields, S., Schneider, C., & Martin, G. S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11089 · Cited by 287
Small G protein Ral and its downstream molecules regulate endocytosis of EGF and insulin receptors
Nakashima, S., Morinaka, K., Koyama, S., Ikeda, M., Kishida, M., Okawa, K., Iwamatsu, A., Kishida, S., & Kikuchi, A. (1999) · The EMBO Journal · doi:10.1093/emboj/18.13.3629 · Cited by 231
Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin
Awasthi, S., Cheng, J., Singhal, S. S., Saini, M. K., Pandya, U., Pikula, S., Bandorowicz-Pikula, J., Singh, S. V., Zimniak, P., & Awasthi, Y. C. (2000) · Biochemistry · doi:10.1021/bi992964c · Cited by 159
RalA and RalB: Antagonistic Relatives in Cancer Cell Migration
Oxford, G., Owens, C. R., Titus, B. J., Foreman, T. L., Herlevsen, M. C., Smith, S. C., & Theodorescu, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1957 · Cited by 139
Aurora-A Phosphorylates, Activates, and Relocalizes the Small GTPase RalA
Lim, K.-H., Brady, D. C., Kashatus, D. F., Ancrile, B. B., Der, C. J., Cox, A. D., & Counter, C. M. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00916-08 · Cited by 126
Self-citationAn Eps Homology (EH) Domain Protein That Binds to the Ral-GTPase Target, RalBP1
Yamaguchi, A., Urano, T., Goi, T., & Feig, L. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31230 · Cited by 126 · cited 1×
“Two independent yeast 2-hybrid library screening studies identified the closely related Reps1 (RalBP1associated Eps homology (EH) domain protein 1) and Reps2/POB1 (partner of RalBP1) proteins that interact with RalBP1 C-terminal sequences distinct from the RhoGAP and Ral binding domains.(43,44) Reps1 and Reps2 contain…”
BackgroundHu, Y., & Mivechi, N. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300788200 · Cited by 101
Matsuzaki, T., Hanai, S., Kishi, H., Liu, Z., Bao, Y., Kikuchi, A., Tsuchida, K., & Sugino, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112472200 · Cited by 85
RalA-Exocyst Complex Regulates Integrin-Dependent Membrane Raft Exocytosis and Growth Signaling
Balasubramanian, N., Meier, J. A., Scott, D. W., Norambuena, A., White, M. A., & Schwartz, M. A. (2010) · Current Biology · doi:10.1016/j.cub.2009.11.016 · Cited by 75
Regulated RalBP1 Binding to RalA and PSD-95 Controls AMPA Receptor Endocytosis and LTD
Han, K., Kim, M.-H., Seeburg, D., Seo, J., Verpelli, C., Han, S., Chung, H. S., Ko, J., Lee, H. W., Kim, K., et al. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000187 · Cited by 71
Ral activation promotes melanomagenesis
Zipfel, P. A., Brady, D. C., Kashatus, D. F., Ancrile, B. D., Tyler, D. S., & Counter, C. M. (2010) · Oncogene · doi:10.1038/onc.2010.224 · Cited by 47 · cited 1×
“It was also recently demonstrated that a majority of human melanoma cells with wild-type NRAS and those cells harboring mutations in NRAS and BRAF have high levels of RalA but not RalB activation.(107) Expression of RalAspecific shRNA in NRAS and BRAF mutant cell lines, and to a lesser extent NRAS and BRAF wild-type c…”
Background
Cited by
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Self-citationTargeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
“On the other hand, Ral signaling is upstream of NF-kB and TBK1, both of which have been implicated as essential genes downstream of K-Ras (Neel et al., 2011; Kashatus, 2013).”
BackgroundRoles for KRAS in Pancreatic Tumor Development and Progression
di Magliano, M. P., & Logsdon, C. D. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.071 · Cited by 400
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
Metadata
- Authors
- Neel, N. F., Martin, T. D., Stratford, J. K., Zand, T. P., Reiner, D. J., & Der, C. J.
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2011-03-01
- Volume
- 2
- Issue
- 3
- Pages
- 275-287
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- OpenAlex
- W2138516325
- Cited by
- 130
- References
- 21
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.